Rates of Progression in Diabetic Retinopathy During Different Time Periods

OBJECTIVE This meta-analysis reviews rates of progression of diabetic retinopathy to proliferative diabetic retinopathy (PDR) and/or severe visual loss (SVL) and temporal trends. RESEARCH DESIGN AND METHODS This systematic literature review and meta-analysis of prospective studies assesses progression of retinopathy among diabetic patients without treatment for retinopathy at baseline. Studies published between 1975 to February 2008 were identified. Outcomes of interest were rates of progression to PDR and/or SVL. Pooled baseline characteristics and outcome measures were summarized using weighted averages of counts and means. Baseline characteristics and outcomes were compared between two periods: 1975–1985 and 1986–2008. RESULTS A total of 28 studies comprising 27,120 diabetic patients (mean age 49.8 years) were included. After 4 years, pooled incidence rates for PDR and SVL were 11.0 and 7.2%, respectively. Rates were lower among participants in 1986–2008 than in 1975–1985. After 10 years, similar patterns were observed. Participants in 1986–2008 studies had lower proportions of PDR and non-PDR at all time points than participants in 1975–1985 studies. CONCLUSIONS Since 1985, diabetic patients have lower rates of progression to PDR and SVL. These findings may reflect an increased awareness of retinopathy risk factors; earlier identification and initiation of care for patients with retinopathy; and improved medical management of glucose, blood pressure, and serum lipids. Differences in baseline characteristics, particularly in the prevalence and severity of retinopathy, could also have contributed to these temporal differences.

[1]  R. Klein,et al.  Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials , 2008, The Lancet.

[2]  H. Parving,et al.  Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial , 2008, The Lancet.

[3]  Xiao-Hua Zhou,et al.  Statistical Methods for Meta‐Analysis , 2008 .

[4]  F. Ferris,et al.  Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium. , 2008, Investigative ophthalmology & visual science.

[5]  H. Parving,et al.  DIRECT Programme Study Group. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. , 2008 .

[6]  T. Wong,et al.  Management of diabetic retinopathy: a systematic review. , 2007, JAMA.

[7]  Helen K. Li,et al.  Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial. , 2007, Archives of ophthalmology.

[8]  Toke Bek,et al.  The relationships between risk factors and the distribution of retinopathy lesions in type 2 diabetes. , 2006, Acta ophthalmologica Scandinavica.

[9]  A. Flyvbjerg,et al.  Prevention and early detection of vascular complications of diabetes , 2006, BMJ : British Medical Journal.

[10]  J. Ludvigsson,et al.  Declining incidence of severe retinopathy and persisting decrease of nephropathy in an unselected population of Type 1 diabetes—the Linköping Diabetes Complications Study , 2004, Diabetologia.

[11]  Stephen J. Aldington,et al.  Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM Complications Study , 1995, Diabetologia.

[12]  N. Congdon,et al.  Important causes of visual impairment in the world today. , 2003, JAMA.

[13]  Stephen W. Sorensen,et al.  Lifetime risk for diabetes mellitus in the United States. , 2003, JAMA.

[14]  B. Zinman,et al.  Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. , 2003, Diabetes care.

[15]  N. Tajima,et al.  Incidence of ESRD and survival after renal replacement therapy in patients with type 1 diabetes: a report from the Allegheny County Registry. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  H. Parving,et al.  Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. , 2003, Diabetes care.

[17]  Francisco Gómez-Ulla,et al.  Digital retinal images and teleophthalmology for detecting and grading diabetic retinopathy. , 2002, Diabetes care.

[18]  Marilyn James,et al.  Cost effectiveness analysis of screening for sight threatening diabetic eye disease , 2000, BMJ : British Medical Journal.

[19]  S. Vitale The Wisconsin Epidemiologic Study of Diabetic Retinopathy: what can we learn at 14 years? , 1998, Ophthalmology.

[20]  R. Klein,et al.  The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. , 1998, Ophthalmology.

[21]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[22]  Uk-Prospective-Diabetes-Study-Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[23]  H. Parving,et al.  Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study , 1997, BMJ.

[24]  T. Batchelder,et al.  The Wisconsin Epidemiologic Study of Diabetic Retinopathy. , 1995, Archives of ophthalmology.

[25]  J Ludvigsson,et al.  Declining incidence of nephropathy in insulin-dependent diabetes mellitus. , 1994, The New England journal of medicine.

[26]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[27]  F. Ferris,et al.  How effective are treatments for diabetic retinopathy? , 1993, JAMA.

[28]  Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. , 1991, Ophthalmology.

[29]  D L DeMets,et al.  The Wisconsin epidemiologic study of diabetic retinopathy. XI. The incidence of macular edema. , 1989, Ophthalmology.

[30]  D L DeMets,et al.  The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. , 1989, Archives of ophthalmology.

[31]  F. Ferris,et al.  Photocoagulation for diabetic macular edema. , 1987, Archives of ophthalmology.

[32]  D L DeMets,et al.  The Wisconsin Epidemiologic Study of Diabetic Retinopathy. VI. Retinal photocoagulation. , 1987, Ophthalmology.

[33]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[34]  Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. , 1985, Archives of ophthalmology.

[35]  J. Fleiss,et al.  Statistical methods for rates and proportions , 1973 .

[36]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.